Winrich Evan J, Tiwari Harsh, Gala Khushboo S, Royer Amor J, Parajuli Dipendra, Vatsalya Vatsalya
Department of Medicine, University of Louisville, Louisville, KY 40202, USA.
Alcohol Research Center, University of Louisville, Louisville, KY 40202, USA.
J Clin Med. 2023 Apr 19;12(8):2968. doi: 10.3390/jcm12082968.
Hypomagnesemia has been documented in alcohol-associated liver disease (ALD). This study aims to characterize hypomagnesemia in alcoholic hepatitis (AH) patients and identify its response with liver injury and severity markers.
A total of 49 male and female AH patients with an age range of 27-66 years were enrolled in this study. Patients were grouped by MELD: MiAH (mild AH < 12 [ = 5]), MoAH (12 ≤ moderate AH ≤ 19 [ = 13]), and SAH (severe AH ≥ 20 [ = 31]). Patients were also evaluated by MELD grouping as non-severe (MELD ≤ 19 [ = 18]) and severe (MELD ≥ 20 [ = 31]). Data were collected on demographics (Age; BMI), drinking history (AUDIT; LTDH), liver injury (ALT; AST), and liver severity (Maddrey's DF; MELD; AST:ALT). Serum magnesium (SMg) levels were tested as SOC lab (normal ≥ 0.85 ≤ 1.10 mmol/L).
SMg was deficient in each group; the lowest in the MoAH patients. The true positivity of SMg values were at a good performance level when compared between severe and non-severe AH patients (AUROC: 0.695, = 0.034). We found that the SMg level < 0.78 mmol/L could predict severe AH (sensitivity = 0.100 and 1-specificity = 0.000) at this true positivity, and subsequently analyzed patients with SMg < 0.78 mmol/L (Gr.4) and ≥0.78 mmol/L (Gr.5). Between Gr.4 and Gr.5, there were clinically as well as statistically significant differences in disease severity as defined by MELD, Maddrey's DF, and ABIC scores.
This study demonstrates the utility of SMg levels to identify AH patients who may have progressed to severe status. The extent of magnesium response in AH patients also corresponded significantly with the prognosis of liver disease. Physicians suspecting AH in patients with recent heavy drinking may use SMg as an indicator to guide further testing, referrals, or treatment.
酒精性肝病(ALD)患者中已发现低镁血症。本研究旨在描述酒精性肝炎(AH)患者的低镁血症特征,并确定其与肝损伤及严重程度标志物的关系。
本研究共纳入49例年龄在27 - 66岁之间的AH患者,男女不限。患者按终末期肝病模型(MELD)分组:轻度AH(MiAH,MELD < 12 [n = 5])、中度AH(MoAH,12 ≤ MELD ≤ 19 [n = 13])和重度AH(SAH,MELD ≥ 20 [n = 31])。患者也按MELD分组评估为非重度(MELD ≤ 19 [n = 18])和重度(MELD ≥ 20 [n = 31])。收集了人口统计学数据(年龄;体重指数)、饮酒史(酒精使用障碍识别测试;终生饮酒量)、肝损伤指标(谷丙转氨酶;谷草转氨酶)和肝脏严重程度指标(马德雷判别函数;MELD;谷草转氨酶:谷丙转氨酶)。血清镁(SMg)水平作为常规实验室检测项目(正常范围≥0.85 ≤ 1.10 mmol/L)。
每组患者均存在SMg缺乏;MoAH组患者的SMg水平最低。在重度和非重度AH患者之间比较时,SMg值的真阳性率处于良好水平(曲线下面积:0.695,P = 0.034)。我们发现,在该真阳性率下,SMg水平< 0.78 mmol/L可预测重度AH(敏感度 = 0.100,1 - 特异度 = 0.000),随后分析了SMg < 0.78 mmol/L的患者(第4组)和≥0.78 mmol/L的患者(第5组)。在第4组和第5组之间,根据MELD、马德雷判别函数和ABIC评分定义的疾病严重程度在临床和统计学上均存在显著差异。
本研究证明了SMg水平在识别可能已进展至重度状态的AH患者方面的作用。AH患者镁缺乏的程度也与肝病预后显著相关。怀疑近期大量饮酒患者患有AH的医生可将SMg作为指导进一步检查、转诊或治疗的指标。